据估计，20- 30%的乙肝病毒感染者能够从治疗中获益。
It is estimated that 20-30% of persons with HBV infection could benefit from treatment.
然而，能够有效对抗乙肝病毒的药物却不能普遍可得，或可供乙肝病毒感染者使用。
However, drugs active against HBV are not widely available or utilized in persons infected with HBV.
卫生保健工作者在为乙肝病毒感染者提供保健时，可能出现意外针刺伤，因此乙肝病毒也对他们构成威胁。
HBV also poses a risk to healthcare workers who sustain accidental needle stick injuries while caring for infected-HBV patients.
1998年首个核苷类似物药物拉米夫定推出之前，慢性乙肝病毒感染者可选的有效治疗途径一直都非常有限。
Effective treatment options for individuals with chronic hepatitis B infection were limited until 1998 when lamivudine, the first nucleoside analogue drug, was introduced.
1998年首个核苷类似物药物拉米夫定推出之前，慢性乙肝病毒感染者可选的有效治疗途径一直都非常有限。
Effective treatment options for individuals with chronic hepatitis B infection were limited until 1998 when lamivudine, the first nucleoside analogue drug, was introduced.
应用推荐